# US 2010/0303820 A1 · Methods of treatment using il-17e antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0303820 A1
- Document ID: US20100303820A1
- Status: Published application
- Kind: A1
- Application number: 12/787,295
- Filed: 2010-05-25
- Published: 2010-12-02
- Earliest claimed: 2000-06-22
- Assignees: Amgen Inc.
- Inventors: Eugene Medlock; Richard Yeh; Scott Michael Silbiger; Gary S. Elliott; Hung Q. Nguyen; Shuqian Jing
- Web page: https://patentgrep.com/patent/US20100303820A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A61K 38/20: Interleukins [IL]
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/54: Interleukins [IL]
- C07K 14/7155: {for interleukins [IL]}
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 2217/052: inducing gain of function
- A01K 2227/105: Murine
- A01K 2267/0381: Animal model for diseases of the hematopoietic system
- A01K 2267/0387: Animal model for diseases of the immune system
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Novel IL-17 like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing IL-17 like polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with IL-17 like polypeptides, agonists, or antagonists thereof.

## Claims

### Claim 1

A method of treating cystic fibrosis, comprising administering to a patient having cystic fibrosis a composition comprising an antagonistic antibody that specifically binds a protein consisting of SEQ ID NO:2.

### Claim 2

A method of treating emphysema, comprising administering to a patient having emphysema a composition comprising an antagonistic antibody that specifically binds a protein consisting of SEQ ID NO:2.

### Claim 3

A method of treating acute respiratory distress syndrome, comprising administering to a patient having acute respiratory distress syndrome a composition comprising an antagonistic antibody that specifically binds a protein consisting of SEQ ID NO:2.
